NASDAQ:KZR - Kezar Life Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.57 -0.69 (-3.25 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$20.57
Today's Range$20.28 - $21.9196
52-Week Range$14.77 - $36.33
Volume25,645 shs
Average Volume65,290 shs
Market Capitalization$406.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Receive KZR News and Ratings via Email

Sign-up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KZR
CUSIPN/A
Phone650-822-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees20
Market Cap$406.24 million
OptionableNot Optionable

Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences Inc (NASDAQ:KZR) announced its quarterly earnings data on Thursday, November, 8th. The company reported ($0.30) EPS for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.18. View Kezar Life Sciences' Earnings History.

When is Kezar Life Sciences' next earnings date?

Kezar Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Kezar Life Sciences.

What price target have analysts set for KZR?

4 brokerages have issued 1 year price targets for Kezar Life Sciences' stock. Their predictions range from $23.00 to $30.00. On average, they expect Kezar Life Sciences' share price to reach $26.50 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

What is the consensus analysts' recommendation for Kezar Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

Has Kezar Life Sciences been receiving favorable news coverage?

Media headlines about KZR stock have been trending somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kezar Life Sciences earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.

Who are some of Kezar Life Sciences' key competitors?

Who are Kezar Life Sciences' key executives?

Kezar Life Sciences' management team includes the folowing people:
  • Mr. John Fowler, Co-Founder, CEO & Director (Age 46)
  • Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 46)
  • Dr. Jack Taunton, Co-Founder
  • Mr. Marc L. Belsky, CFO & Sec. (Age 63)
  • Michael Wolfe, Director of Fin. & Operations

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

When did Kezar Life Sciences' lock-up period expire?

Kezar Life Sciences' lock-up period expired on Tuesday, December 18th. Kezar Life Sciences had issued 5,000,000 shares in its initial public offering on June 21st. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Since the end of Kezar Life Sciences' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $20.57.

How big of a company is Kezar Life Sciences?

Kezar Life Sciences has a market capitalization of $406.24 million. Kezar Life Sciences employs 20 workers across the globe.

What is Kezar Life Sciences' official website?

The official website for Kezar Life Sciences is http://www.kezarlifesciences.com.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]


MarketBeat Community Rating for Kezar Life Sciences (NASDAQ KZR)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  81
MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote "Outperform" if you believe KZR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel